BioAtla (NASDAQ:BCAB) PT Lowered to $10.00

BioAtla (NASDAQ:BCABGet Free Report) had its price target cut by equities research analysts at HC Wainwright from $17.00 to $10.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock.

A number of other equities analysts have also issued reports on the company. JPMorgan Chase & Co. reduced their target price on BioAtla from $17.00 to $14.00 and set an “overweight” rating for the company in a research note on Monday, September 25th. JMP Securities restated a “market outperform” rating and set a $12.00 target price on shares of BioAtla in a research report on Wednesday, August 2nd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.80.

View Our Latest Stock Report on BioAtla

BioAtla Trading Down 6.3 %

Shares of BCAB stock opened at $1.65 on Tuesday. The business’s fifty day simple moving average is $1.85 and its 200-day simple moving average is $2.69. The company has a market cap of $78.87 million, a PE ratio of -0.62 and a beta of 0.50. BioAtla has a 12-month low of $1.24 and a 12-month high of $11.73.

Institutional Investors Weigh In On BioAtla

Several institutional investors have recently bought and sold shares of BCAB. Barclays PLC purchased a new position in BioAtla in the 2nd quarter worth approximately $27,000. Virtu Financial LLC acquired a new position in shares of BioAtla in the first quarter worth $28,000. Tower Research Capital LLC TRC grew its stake in shares of BioAtla by 71.6% in the first quarter. Tower Research Capital LLC TRC now owns 11,295 shares of the company’s stock worth $30,000 after acquiring an additional 4,711 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of BioAtla in the third quarter worth $37,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of BioAtla during the second quarter worth $38,000. 71.67% of the stock is currently owned by institutional investors and hedge funds.

About BioAtla

(Get Free Report)

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.

Recommended Stories

Analyst Recommendations for BioAtla (NASDAQ:BCAB)

Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with's FREE daily email newsletter.